search
Type 2 diabetes
Trends
- 1New tool predicts 31-day readmission risk in type 2 diabetes▼A nomogram incorporating nutritional risk for predicting 31-day unplanned readmission in adults with type 2 diabetes mellitus using LASSO regression
Researchers have developed a nomogram that combines nutritional risk screening with LASSO regression to predict the likelihood of unplanned readmission within 31 days for adults with type 2 diabetes. The tool is aimed at helping clinicians identify high-risk patients early and target follow-up care, with nutritional status highlighted as a key factor in hospital returns.
- 2Oral GLP-1 pill safiglipron shows promise in early type 2 diabetes trial▼Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.
- 3
Eli Lilly's experimental drug retatrutide is drawing global attention after new trial results showed people lost up to 25% of their body weight, with patients who have Type 2 diabetes shedding as much as 60 pounds, or roughly 21% of their weight. Outlets including Reuters, NBC News and Ars Technica describe it as potentially the most powerful obesity drug yet, and searches are spiking in the US, UK and Brazil.
- 4Large genetic study probes type 2 diabetes in East Asian populations●Decomposing population differences in type 2 diabetes through a high-resolution GWAS of ~600,000 individuals with East Asian ancestry
Researchers have published a high-resolution genome-wide association study of roughly 600,000 people with East Asian ancestry, aiming to decompose population-level differences in type 2 diabetes risk. The work, appearing in Nature, identifies ancestry-specific genetic factors that may explain why diabetes patterns differ between East Asian and European populations, with potential implications for risk prediction and treatment across populations.
- 5Retatrutide Shows Record Weight Loss in Type 2 Diabetes Trial▼Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes
Eli Lilly's triple agonist retatrutide has been reported to push weight loss to new levels among patients with type 2 diabetes, according to Inside Precision Medicine. The drug, which targets three hormone receptors, is being studied as one of the most powerful obesity and diabetes treatments in development, extending gains seen with tirzepatide and semaglutide.